{"output": [["BioNTech", "ORG", "Raise", "$270 million", "FIN_INSTRUMENT"], ["BioNTech", "ORG", "Operate_In", "Germany", "GPE"], ["BioNTech", "ORG", "Has", "close to $950 million", "FIN_INSTRUMENT"], ["BioNTech", "ORG", "Participates_In", "cancer immunotherapies development", "CONCEPT"], ["BioNTech", "ORG", "Will_IPO", "None", "None"], ["BioNTech", "ORG", "Control", "around 700 employees", "PERSON"], ["BioNTech", "ORG", "Has", "corporate partnerships", "SECTOR"], ["BioNTech", "ORG", "Has", "majority owners Thomas and Andreas Struengmann", "PERSON"], ["BioNTech", "ORG", "Has", "latest Series A financing", "FIN_INSTRUMENT"], ["Personalized cancer vaccine", "PRODUCT", "Impact", "cancer patients", "PERSON"], ["Personalized cancer vaccine", "PRODUCT", "Relate_To", "immunotherapy drugs", "PRODUCT"], ["Personalized cancer vaccine", "PRODUCT", "Used_By", "Roche", "ORG"], ["Personalized cancer vaccine", "PRODUCT", "Use", "messenger RNA", "CONCEPT"], ["Immunotherapy drugs", "PRODUCT", "Produce", "Merck & Co", "ORG"], ["Immunotherapy drugs", "PRODUCT", "Produce", "Bristol-Myers Squibb", "ORG"], ["Immunotherapy drugs", "PRODUCT", "Produce", "Roche", "ORG"]], "published": "2018-01-04T11:14:00.000+02:00"}